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ABSTRACT.
Purpose: We describe eight patients with juvenile idiopathic arthritis-related
chronic uveitis, who received a fluocinolone acetonide implant (FAI, Retisert,
Bausch&Lomb) in one eye. All patients had poor visual acuity (VA) due to
persistent macular oedema in one or both eyes despite treatment with
antirheumatic medication.
Methods: Median age of the patients was 22.9 years (range, 14.1–39.7) and
duration of uveitis 13.0 years (range, 6.8–28.4) at FAI implantation. Median
preoperative best-corrected visual acuity (BCVA) was 0.1 (range, 0.05–0.4) and
Standardization of Uveitis Nomenclature, SUN-grade was SUN 2+ (range, 0.5–
4.0). All patients had been treated extensively with systemic corticosteroids and
antirheumatic drugs by the time of FAI implantation. The median follow-up time
was 5.3 years (range, 4.4–6.3).
Results: Macular edema resolved in amedian time of 0.2 years (range, 0.04–0.39)
after the FAI implantation. Themedian BCVAwas 0.5–0.63 (range, 0.1–1.0) from
1 to 5 years of follow-up. Macular edema did not recur in 5 eyes after the
implantation. In three eyes, the macular oedema relapsed at 2.7, 2.9 and 5.5 years
of follow-up. All our patients needed antirheumatic drugs in addition to the FAI to
treat their macular edema. During the follow-up, 7 eyes required further
intraocular operations: 4 cataract operations, 4 intraocular pressure -lowering
operations and 1 retinal detachment surgery were performed.
Conclusion: Fluocinolone acetonide implant is a valuable option in the treatment
of persistent macular edema associated with JIA-related uveitis refractory to
systemic treatments.
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Introduction
Persistent macular oedema is the most
common cause of visual impairment in
chronic uveitis (Tomkins-Netzer et al.
2014). Macular oedema occurs in up to
15% of patients with juvenile idiopathic
arthritis (JIA)-related uveitis (Angeles-
Han et al. 2015; de Boer et al. 2015). In
JIA-related uveitis, it associates with
vision loss (deBoer et al. 2015) and legal
blindness (Angeles-Han et al. 2015).
Macular oedema is more common
among patients with longer duration of
uveitis (de Boer et al. 2015). There is no
drug of choice to treat macular oedema
associated with JIA uveitis. Potentially
eﬀective antirheumatic drugs include
cyclosporine, inﬂiximab and adali-
mumab (Diaz-Llopis et al. 2008; Pato
et al. 2011; Heiligenhaus et al. 2012;
Garcıa-De-Vicu~na et al. 2013). Intrav-
itreal corticosteroids have been used
successfully in treating paediatric uveitic
macular oedema (Sallam et al. 2008;
Sella et al. 2015). Sustained release
intravitreal corticosteroid implants
have been suggested for uveitic macular
oedema when systemic antirheumatic
therapy fails (Foster et al. 2016). Fluo-
cinolone acetonide implant (FAI, Retis-
ert, Bausch & Lomb) has been shown
to eﬀectively control inﬂammation and
macular oedema in eyes with uveitis
(Kempen et al. 2015).
We describe eight JIA-related uveitis
patients with sight-threatening chronic
macular oedema resistant to disease-mod-
ifying antirheumatic drugs (DMARDs),
biologic drugs and systemic corticos-
teroids. Periocular and intravitreal
corticosteroid were given to two
patients prior FAI implantation. Fluo-
cinolone acetonide implantation was
performed in eight eyes with favourable
results.
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Patients and Methods
Nine ﬂuocinolone acetonide implants
were implanted in 2010–2012 in Hel-
sinki University Hospital, Department
of Ophthalmology to treat persistent
macular oedema in JIA-related uveitis.
Eight patients with eight FAI
implanted eyes were included in the
analysis after one patient dropped from
the follow-up after a good initial
response to FAI. Despite treatment
with topical and systemic (eight
patients), periocular (1), intravitreal
corticosteroids (1 dexamethasone
implant), DMARDs (8) and biologic
drugs (8), all patients had developed
resistant sight-threatening macular
oedema. FAI implantation remained
the last eﬀort. Four eyes were phakic
and four pseudophakic. Two eyes had
been diagnosed with secondary glau-
coma and one had had IOP-lowering
surgery prior to the FAI implantation.
FAI was implanted via pars plana in
one eye of each patient. One patient
had a more extensive vitreoretinal
operation in addition to FAI implan-
tation due to grave epiretinal mem-
brane formation. All patients were
followed up every 1–12 weeks. Corti-
costeroid and antirheumatic medica-
tions were moderated pre- and
postoperatively according to the activ-
ity of uveitis and arthritis in coopera-
tion with rheumatologists. The ethics
committee of the Helsinki University
Hospital approved this study, and its
design complies with the Declaration of
Helsinki.
The following data were recorded:
age at onset of uveitis, age at onset of
JIA diagnosed by a paediatric
rheumatologist, antirheumatic medica-
tion, best-corrected visual acuity in
decimal notations (BCVA) and uveitis
activity in Standardization of Uveitis
Nomenclature (SUN) grading (Jabs
et al. 2005) preoperatively and during
the follow-up, ocular complications
and intraocular operations. (OCT)
was used to detect the macular
oedema. Due to media opacities and
pupillary abnormalities in these uvei-
tis eyes, resolution of the images was
not high enough for standard pro-
gression analysis. The Statistical
Package for the Social Sciences SPSS
19 (IBM Corp., NY) was used. All
tests were two-sided, and p < 0.05
was considered signiﬁcant.
Results
A ﬂuocinolone acetonide intravitreal
implant was implanted in one eye of
eight JIA-uveitis patients. (Table 1)
The median age was 22.9 years (range,
14.1–39.7) and duration of uveitis
13.0 years (range, 6.8–28.4) at the time
of implantation.
Six patients had been diagnosed with
uveitis at their ﬁrst ophthalmological
screening (Papadopoulou et al. 2017).
Two patients were diagnosed with
paediatric anterior uveitis at 13.9 and
7.3 years of age and later with idio-
pathic arthritis. According to EULAR
criteria (Wood 1978), ﬁve patients had
juvenile idiopathic oligoarthritis, three
patients had juvenile idiopathic pol-
yarthritis and one patient was diag-
nosed with juvenile spondyloarthritis.
The median preoperative BCVA was
0.1 (range, 0.05–0.4), and the median
SUN grade was SUN 2+ (range, 0.5–
4.0) in the treated eye. The uveitis was
unilateral in two and bilateral in six
patients. Bilateral macular oedema was
present in three patients (BCVA ≤0.1
bilaterally) preoperatively. Preopera-
tive BCVA of the fellow eye was 1.0
in ﬁve patients. The median follow-up
was 5.0 years; range, 3.5–6.0.
Macular oedema resolved in a med-
ian time of 0.2 years (range, 0.04–0.39)
in the treated eyes (Figure 1). The
median BCVA was 0.5–0.63 from 1 to
5 years of follow-up (Table 2, Fig-
ure 2). In three eyes, macular oedema
relapsed at 2.7, 2.9 and 5.5 years after
the FAI implantation. The relapses
were resolved with changes in antirheu-
matic medication in two and with a
dexamethasone implant in one patient.
Besides three anterior segment activa-
tions of three eyes (at 2.9, 3.1 and
4.7 years), all treated eyes stayed
≤SUN 1+ during the follow-up.
In the six patients with binocular
uveitis, ﬁve patients had at least one
eye ≥0.63 at the end of the follow-up.
(BCVA) was ≤0.16 binocularly in one
patient due to macular scarring.
At the last follow-up, six patients
were treated with topical corticos-
teroids, one with systemic corticos-
teroids, six patients were on DMARDs
and ﬁve needed biologic drugs to treat
their uveitis, arthritis or both.
Four eyes had had a cataract oper-
ation before and cataract was operated
on in the remaining four eyes 0.5–
1.2 years after FAI implantation.
Two eyes had been diagnosed with
secondary glaucoma prior the FAI
implantation. The median preoperative
IOP was 10 mmHg (range, 8–20). The
IOP of two eyes has stayed ≤21 mmHg
during the follow-up. The IOP of six
eyes rose to >21 mmHg at 0.5–4.7 years
of follow-up (Figure 3). The IOP of two
of these eyes has stayed ≤26 mmHgwith
antiglaucomatous medication and with-
out IOP-lowering surgeries. Four eyes
had IOP ≥30 mmHg on maximal toler-
ated antiglaucomatous medication and
were operated on 0.3–2.2 years after
the initial IOP rise >21 mmHg, 0.9–
5.2 years after the FAI implantation.
One of these eyes had secondary glau-
coma prior the FAI implantation. One
trabeculectomy, one deep sclerectomy
and twodrainage implant surgeries were
performed. By the end of the follow-up,
one of these eyes was on antiglaucoma-
tousmedication, andnoadditional IOP-
lowering surgeries had been performed.
Retinal detachment occurred in one eye
that had had epiretinal membrane peel-
ing in addition to FAI implantation.
The eye was operated on successfully
one month after FAI implantation. No
implants were removed, and no dissoci-
ation of FAIs has been noticed to date.
Discussion
Macular oedema is a sight-threatening
complication of JIA uveitis (Tomkins-
Netzer et al. 2014; Angeles-Han et al.
2015; de Boer et al. 2015). It is more
Table 1. Characteristics of the eight patients.
Median Range
Age at the onset of uveitis (years) 8.3 3.1–14.1
Age at operation (years) 22.9 14.1–39.7
Duration of uveitis at operation (years) 13.0 6.8–28.4
Preoperative BCVA 0.1 0.05–0.4
Preoperative SUN grade 2.0 0.5–4.0
BCVA = best-corrected visual acuity; SUN = standardization of uveitis nomenclature.
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common in patients with longer dura-
tion of uveitis (de Boer et al. 2015), like
in our patients who had had uveitis for
a median time of 13.0 years.
For treating uveitic macular oedema,
corticosteroids and antirheumatic drugs
are potentially eﬀective (Pato et al.
2011). Intravitreal corticosteroids have
been used to resolve macular oedema in
uveitis balancing the potential beneﬁts
against the high complication risks
(Sallam et al. 2008; Arcinue et al. 2013;
Sella et al. 2015). When antirheumatic
treatment proved to be insuﬃcient in
treating the chronic macular oedema of
our JIA-uveitis patients, intravitreal ﬂuo-
cinolone implant remained the lastoption.
Persistent macular oedema was
resolved with a ﬂuocinolone acetonide
implant in all eight eyes of eight
patients with JIA-related uveitis. Three
patients’ macular oedema relapsed dur-
ing the follow-up. Similar results have
been reported in the MUST trial where
about two-thirds of eyes with uveitic
macular oedema due to intermediate or
posterior uveitis improved with a FAI.
In the MUST trial, FAI and systemic
antirheumatic treatment were as eﬀec-
tive in a follow-up up to 4.5 years
(Multicenter Uveitis Steroid Treatment
(MUST) Trial Research Group et al.
2015). All our patients needed disease-
modifying and biologic antirheumatic
drugs in addition to the FAI to treat
their macular oedema. Only two
patients did not need antirheumatic
therapy by the last follow-up.
Postoperative FAI complications are
frequent (Foster et al. 2016;Multicenter
Uveitis Steroid Treatment (MUST)
Trial Research Group et al. 2015, Arci-
nue et al. 2013; Sen et al. 2016). All
phakic patients underwent a cataract
operation postimplantation in our
study. Our young patient group had a
high rate (four of eight patients) of IOP-
lowering surgeries. Young age at
implantation has been associated with
IOP rise after the FAI implantation
(Parekh et al. 2015). The success rate of
the four IOP-lowering surgeries in our
study was high: no reoperations were
performed and only one patient needed
antiglaucomatous medication by the
last follow-up. One retinal detachment
was operated on successfully in one eye
that had undergone epiretinal mem-
brane peeling in addition to FAI
implantation.Despite the complications
and relapses, the improvement in (VA)
was maintained until the last follow-up
in all our patients.
In a study by Arcinue et al., no
signiﬁcant diﬀerences were seen in
visual acuity or inﬂammation after a
Fig. 1. OCT images prior to the ﬂuocinolone acetonide implant operation (A), 2 weeks (B), 2 years (C) and 5 years (D) after the operation.
Table 2. Best-corrected visual acuity in decimal notation of the ﬂuocinolone acetonide implant
eyes preoperatively and at 1–5 years of follow-up.
No of
eyes
Median
BCVA Range p value*
Preoperative 8 0.10 0.05–0.4
At 1 year 8 0.50 0.1–1.0 0.018*
At 2 years 8 0.56 0.16–1.0 0.012*
At 3 years 8 0.56 0.16–1.0 0.018*
At 4 years 8 0.52 0.125–1.0 0.018*
At 5 years 7 0.63 0.32–0.7 0.018*
BCVA = Best-corrected visual acuity.
* Wilcoxon signed-ranks test for the improvement from the preoperative BCVA.
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sustained release intravitreal dexam-
ethasone implant compared with ﬂuo-
cinolone implant in panuveitis eyes.
Higher rates of complications and
longer survival time for a second
implant were found among the FAI
eyes (Arcinue et al. 2013). Prior the
FAI implantation, only one of our
patients was treated with a sustained
release intravitreal dexamethasone
implant with which the macular
oedema did not resolve.
In our experience, intravitreal ﬂuoci-
nolone acetonide implants can be
considered a last resort treatment for
JIA-uveitis patients with poor vision
due to macular oedema that is resistant
to systemic corticosteroids and
antirheumatic treatment. Because of
the potential FAI-related complica-
tions, close monitoring of the implanted
eyes is needed for years after the
implantation.
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Fig. 2. Visual acuity in decimal notation of eight patients at implantation and at 1–5 years of
follow-up. Macular oedema relapsed in eyes numbered 2, 5 and 6.
Fig. 3. Intraocular pressure (mmHg) until an intraocular pressure lowering operation marked
with ■ or last follow-up of intraocular pressure.
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